Literature DB >> 2313082

Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors.

L S Elting1, N Khardori, G P Bodey, V Fainstein.   

Abstract

Factors predisposing to clinically significant nosocomial infection with Xanthomonas maltophilia were examined in a matched case-control study using multivariate techniques. Sixteen cases occurred among cancer patients in a six-month period, including an apparent cluster of three cases in an intensive care unit. These infections were unusually serious; eight patients had disseminated infection caused by X maltophilia and six died as a result of their infections. Among the 64 factors that were examined, therapy with broad-spectrum antibiotics and central venous catheterization were found to significantly increase susceptibility to infection. Therapy with imipenem was more than ten times more frequent among cases than among controls (p less than .001). All fatal infections occurred in patients who had received imipenem, including two patients who died before the organism could be identified and appropriate therapy instituted. Infection with X maltophilia should be suspected in patients who develop superinfection while receiving imipenem, and prompt therapy should be instituted to improve chances of survival. Because a common environmental source of X maltophilia was not identified, further study is necessary to determine specific preventive measures.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2313082     DOI: 10.1086/646136

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  33 in total

1.  Pseudo-, Xantho-, and now Stenotrophomonas maltophilia: New kid on the block.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1996-03

2.  Antibiotic resistance of Stenotrophomonas maltophilia strains isolated from captive snakes.

Authors:  P Hejnar; M Kolár; P Sauer
Journal:  Folia Microbiol (Praha)       Date:  2010-03-25       Impact factor: 2.099

3.  Is the prevalence of Stenotrophomonas maltophilia isolation and nosocomial infection increasing in intensive care units?

Authors:  E Meyer; F Schwab; P Gastmeier; H Rüden; F D Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-11       Impact factor: 3.267

4.  A new selective differential medium for isolation of Stenotrophomonas maltophilia.

Authors:  K G Kerr; M Denton; N Todd; C M Corps; P Kumari; P M Hawkey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-07       Impact factor: 3.267

5.  Stenotrophomonas maltophilia in the respiratory tract of medical intensive care unit patients.

Authors:  B Saugel; K Eschermann; R Hoffmann; A Hapfelmeier; C Schultheiss; V Phillip; F Eyer; K-L Laugwitz; R M Schmid; W Huber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-07       Impact factor: 3.267

Review 6.  Epidemiology of β-Lactamase-Producing Pathogens.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

7.  A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors:  S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

8.  Stenotrophomonas maltophilia in cystic fibrosis patients.

Authors:  S Ballestero; I Vírseda; H Escobar; L Suárez; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-08       Impact factor: 3.267

9.  Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment.

Authors:  F P Laing; K Ramotar; R R Read; N Alfieri; A Kureishi; E A Henderson; T J Louie
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

10.  Diversity of nosocomial Xanthomonas maltophilia (Stenotrophomonas maltophilia) as determined by ribotyping.

Authors:  P Gerner-Smidt; B Bruun; M Arpi; J Schmidt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.